SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Nectar Lifesciences - Quaterly Results

13 Nov 2021 Evaluate
A decrease in the sales to Rs. 3645.70 millions was observed for the quarter ended September 2021. The sales stood at Rs. 4277.29 millions during the similar quarter previous year.The Total Profit for the quarter ended September 2021 of Rs. 18.62 millions grew from Rs.-73.08 millionsOperating profit for the quarter ended September 2021 rose to 325.55 millions as compared to 320.08 millions of corresponding quarter ended September 2020.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202103 202003 % Var
Sales 3645.70 4277.29 -14.77 7490.23 8161.61 -8.23 15428.96 23631.57 -34.71
Other Income 50.97 5.30 861.70 102.43 10.48 877.39 27.22 40.06 -32.05
PBIDT 325.55 320.08 1.71 733.42 492.60 48.89 1129.49 2223.33 -49.20
Interest 180.09 278.84 -35.41 437.54 557.53 -21.52 1120.32 1258.23 -10.96
PBDT 145.46 41.24 252.72 295.88 -64.93 -555.69 -243.98 965.10 -125.28
Depreciation 141.54 150.93 -6.22 284.32 301.44 -5.68 602.53 607.66 -0.84
PBT 3.92 -109.69 -103.57 11.56 -366.37 -103.16 -846.51 357.44 -336.83
TAX -14.70 -36.61 -59.85 -27.75 -125.05 -77.81 -115.04 56.83 -302.43
Deferred Tax -14.70 -36.61 -59.85 -27.75 -125.05 -77.81 -200.90 40.21 -599.63
PAT 18.62 -73.08 -125.48 39.31 -241.32 -116.29 -731.47 300.61 -343.33
Equity 224.26 224.26 0.00 224.26 224.26 0.00 224.26 224.26 0.00
PBIDTM(%) 7.75 6.55 18.27 9.79 6.04 62.23 6.41 8.42 -23.95

Nectar Lifesciences Share Price

12.26 0.32 (2.68%)
15-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1696.65
Dr. Reddys Lab 1218.30
Cipla 1226.65
Zydus Lifesciences 936.00
Lupin 2339.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×